Genitope Corporation (NASDAQ:GTOP) today announced that, on August 7, 2008, it received a staff determination letter from The Nasdaq Stock Market ("Nasdaq") formally notifying Genitope that it has not regained compliance with the minimum $1.00 per share bid price requirement for continued inclusion on the Nasdaq Global Market under Marketplace Rule 4450(a)(5) and that, unless appealed, trading in Genitope's common stock will be suspended.

Genitope Corporation (NASDAQ:GTOP) today announced that, on May 21, 2008, it received a staff determination letter from The Nasdaq Stock Market ("Nasdaq") indicating that, as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2008, Genitope no longer complied with Nasdaq's filing requirements for continued listing as set forth in Marketplace Rule 4310(c)(14), and that its securities are, therefore, subject to trading suspension and delisting.

Genitope Corporation (Genitope, NASDAQ: GTOP) today announced that a summary of the data from its pivotal Phase 3 clinical trial examining the use of MyVax® personalized immunotherapy (MyVax) in previously untreated follicular B-cell non-Hodgkin's lymphoma (fNHL) patients is available on the Investor Relations section of Genitope's Web site at http://ir.genitope.com.

Genitope Corporation (NASDAQ: GTOP) today announced that, on March 6, 2008, it received a staff deficiency letter from The Nasdaq Stock Market ("Nasdaq") indicating that, as a result of the resignation of Stanford C.

Genitope Corporation (NASDAQ:GTOP) today announced that it intends to adjourn its special meeting of stockholders scheduled to be held on Tuesday, March 11, 2008 and reconvene the meeting on Friday, March 14 at 10:00 am PT at 6900 Dumbarton Circle, Fremont, CA 94555.